By David McCombs, Vincent Shier, Eugene Goryunov, Dina Blikshteyn, and Brooke Cohen, Haynes Boone
With “low-hanging fruit” drugs already in the market, biopharma companies are finding it more difficult to discover the next blockbuster treatment. Artificial intelligence (AI) has become a new arrow in the drug discovery quiver. But how do you patent AI-assisted drug discovery? Attorneys from Haynes Boone provide recommendations.
As protein engineering and manufacturing technologies evolve, there is a need for flexible, customized strategies that balance cost, speed, and risk to accelerate development and approval of biotherapeutics.
Experts answer questions from a recent webinar about the challenges when moving a bioconjugate candidate from early development to the clinic, as well as key considerations for de-risking this journey.